Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial.

Hasegawa K, Colombo N, Tewari KS, Dubot C, Cáceres MV, Lorusso D, Shapira-Frommer R, Salman P, Yañez E, Gümüs M, de Mendoza MOH, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Jensen E, Toker S, Monk BJ

Open source

DOI: 10.1001/jamaoncol.2026.3547
Published: 2026 Sep 10
Container: JAMA oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamaoncol.2026.3547,
  title = {Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial.},
  author = {Hasegawa K and Colombo N and Tewari KS and Dubot C and Cáceres MV and Lorusso D and Shapira-Frommer R and Salman P and Yañez E and Gümüs M and de Mendoza MOH and Samouëlian V and Castonguay V and Arkhipov A and Tekin C and Jensen E and Toker S and Monk BJ},
  year = {2026},
  journal = {JAMA oncology},
  doi = {10.1001/jamaoncol.2026.3547},
  url = {https://doi.org/10.1001/jamaoncol.2026.3547}
}

RIS

TY  - JOUR
TI  - Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial.
AU  - Hasegawa K
AU  - Colombo N
AU  - Tewari KS
AU  - Dubot C
AU  - Cáceres MV
AU  - Lorusso D
AU  - Shapira-Frommer R
AU  - Salman P
AU  - Yañez E
AU  - Gümüs M
AU  - de Mendoza MOH
AU  - Samouëlian V
AU  - Castonguay V
AU  - Arkhipov A
AU  - Tekin C
AU  - Jensen E
AU  - Toker S
AU  - Monk BJ
PY  - 2026
JO  - JAMA oncology
DO  - 10.1001/jamaoncol.2026.3547
UR  - https://doi.org/10.1001/jamaoncol.2026.3547
ER  -

APA

K, H., N, C., KS, T., C, D., MV, C., D, L., R, S., P, S., E, Y., M, G., MOH, D. M., V, S., V, C., A, A., C, T., E, J., S, T., & BJ, M. (2026). Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial.. JAMA oncology. https://doi.org/10.1001/jamaoncol.2026.3547

Source records

pubmed · retrieved 2026-09-25T10:50:11.866Z